SlideShare a Scribd company logo
1 of 18
Download to read offline
Advanced Systems for Rapid Human Identification
          and Next Generation Sequencing
          Stevan Jovanovich, Ph.D.




Proprietary and IntegenX Confidential | 6/27/2012
Overview
Who We Are
         • Growth-stage life science company, with commercial
           operations
                   • Next Generation Sequencing products on the market
         • RapidHIT™ 200 Rapid Human ID System launching
           in Q3
         • 2011 revenues of $4.5M: expected to more than
           triple in 2012
         • All products covered by proprietary and/or >500
           licensed patents
         • $75M in private equity; $24M in grants and contracts:
           DARPA, DTRA, DHS, NIH


2 | Proprietary and IntegenX Confidential | 6/27/2012
Experienced Executive Management Team
                             Stevan Jovanovich, Ph.D. – Co-Founder & CEO
                               • VP of Global Research at Amersham Biosciences
                               • ~$100 M funding at IntegenX with over 40 patents and publications
                             Dennis Harris, Ph.D. – Co-Founder & CSO
                               • CSO at Millipore and Serologicals Corporation
                               • VP R&D North America Amersham Pharmacia Biotech
                             David Smith – COO
                               • CFO at Thoratec, Chiron, and Anergen
                               • Leadership positions at Genentech, IBM and Syntex in North America, Asia and Europe
                             Howard Goldstein – EVP, Commercial Affairs
                               • 30+ years sales and marketing leadership building companies
                               • VP Molecular Devices, Amnis, Incyte, MDCC; CEO at Entigen and Arcxis
                             Ezra van Gelder – EVP, Research & Development
                               • 20+ years engineering management
                               • VP Development GE Healthcare, KLA Tencor
                             Debara Frost – VP, Operations
                               • VP Operations at Applied Biosystems
                               • VP Customer Services and Distribution at Applied Biosystems

3 | Proprietary and IntegenX Confidential | 6/27/2012
Product Solutions
Rapid Human Identification – RapidHIT™ 200
         Need Rapid answers for DNA human identification for defense,
              law enforcement, IQ, and DHS agencies
  Solution Sample-to-answer in less than 90 min
      Market DNA-based rapid identification $5B market in 2015

Next-Gen Sequencing Library Preparation – Apollo™ 324
         Need Human error and lack of platform flexibility in DNA and RNA
              sequencing prep
  Solution Walk-away automation that serves multiple sequencing platforms
      Market $2B total sequencing market

Room Temperature Stabilization and Storage – GenPlate™ and GenTegra™
         Need Eliminate -80°C and cold chain
  Solution Inorganic stabilization and protection
      Market DNA-RNA based sample storage U.S. market $1B in 2015


4 | Proprietary and IntegenX Confidential | 6/27/2012
DNA Forensics and Rapid Human Identification
DNA is the ultimate biometric
         •   Personal, but shows identity and kinship
         •   Almost impossible to disguise or change
         •   DNA evidence is standard in many parts of the world
         •   CSI effect
Short Tandem Repeats (STR) of DNA
are used to identify people
In the US, 13 STRs are used in the
Combined DNA Index System (CODIS)
Rapid DNA identification opens up new horizons
         • Screening of arrestees, detainees, immigrants, and evidence
         • Actionable intelligence

5 | Proprietary and IntegenX Confidential | 6/27/2012
Rapid Human Identification: RapidHIT™ 200

  The traditional HID process can take days to months:

In                                                                                    Out
Swabs                                                                                DNA
Blood                                                                                Identity
Semen
Etc.
                                                         Sample in, profile out
                                                         Results in <90 minutes
                                                         Minimal training required
                                                         Point-of-action solution
                                                         Produces CODIS data and can query
                                                         databases to give answers

 6 | Proprietary and IntegenX Confidential | 6/27/2012
RapidHIT™ 200: The Complete Human ID Solution
                                                                        Sample
                                                                    3   Control


                                                        4   Swabs




 1         Anode




                                                                    2   Buffer




7 | Proprietary and IntegenX Confidential | 6/27/2012
RapidHIT™ 200 results data                                                       02-29-2012


                                                        Sample 60M Buccal Swab
                                                        Capillaries 2 and 6




8 | Proprietary and IntegenX Confidential | 6/27/2012
RapidHIT ™ 200
                                                           Heterozygous peak balance is excellent


            Sample                                                                     Sample

       Cap2: 60M Buccal                                                            Cap6: 60M Buccal
                              Alleles        Pk Ht (rfu)    Pk Ht (rfu)   PHR(%)                      Alleles   Pk Ht (rfu)   Pk Ht (rfu)   PHR(%)
           D3S1358            17,17           100882           n/a         n/a        D3S1358         17,17     110501           n/a         n/a
             THO1               6,7           13284          15819        84.0%         THO1           6,7       16201         21311        76.0%
            D21S11            28,30           42017          37641        89.6%        D21S11         28,30      44578         48880        91.2%
            D18S51            13,14           59075          54996        93.1%        D18S51         13,14      61880         61370        99.2%
            PentaE             7,10           32751          32799        99.9%        PentaE          7,10      34899         30145        86.4%


            D5S818            12,12           137731           n/a         n/a         D5S818         12,12     144917           n/a         n/a


                                                87%                                                             83%
            D13S17             9,13           45463          40397        88.9%        D13S17          9,13      53851         36820        68.4%
            D7S820            10,11           56523          44707        79.1%        D7S820         10,11      48710         46579        95.6%
           D16S539             8,12           29209          23011        78.8%       D16S539          8,12      18606         27570        67.5%
            CSF1PO            10,12           30609          38897        78.7%        CSF1PO         10,12      29716         29261        98.5%
            PentaD            11,13           35174          30636        87.1%        PentaD         11,13      46835         28881        61.7%


             Amel               X,Y           37292          33314        89.3%         Amel           X,Y       36597         40877        89.5%
             vWA              15,18           19084          21006        90.9%         vWA           15,18      27689         20669        74.6%
           D8S1179            13,13           49611            n/a         n/a        D8S1179         13,13      54902           n/a         n/a
             TPOX              9,10            6724           5765        85.7%         TPOX           9,10       6230          6932        89.9%
             FGA              19,19           19350            n/a         n/a           FGA          19,19      15718           n/a         n/a




9 | Proprietary and IntegenX Confidential | 6/27/2012
Rapid DNA-based Human Identification Markets
Law Enforcement
        •    Real-time screening of arrestees
        •    Property crimes and non-evidentiary samples
        •    Forensic identification and casework samples
        •    Terrorists and organized crime




12 | Proprietary and IntegenX Confidential | 6/27/2012
RapidHIT 200 Will Help Solve Property Crime
DNA is highly effective for property crime investigation
Backlogs in crime labs typically prevent use of DNA for property crimes
Deployment of RapidHIT 200 will allow police to quickly focus
investigations and clear cases

                                                                                 Start of DNA use for
                                                                                 high volume crimes




               Effectiveness and Cost Efficiency of DNA Evidence in Volume Crime - Denver Colorado Site Summary
               Simon Ashikhmin et al
15 | Proprietary and IntegenX Confidential | 6/27/2012
Rapid DNA-based Human Identification Markets
Defense
        • Identifying the opposition in
          asymmetric warfare
        • Field-based antiterrorism
        • Identifying suspects in raids
        • Using DNA to unravel the
          network
        • Linking IEDs to bomb makers
        • Finding captured soldiers



IntegenX is funded to develop
and deliver systems to DoD

16 | Proprietary and IntegenX Confidential | 6/27/2012
DoD Field Demonstration, May 2012
DoD Joint Forces Invite-Only Capabilities Demonstration
     • Goal = Field forward capabilities for the war-fighter
       (Actionable Intelligence)
     • Format = Hands-on, tactical scenarios
Week 1 - Prove your technology
     • Operational by non-expert personnel - 9 min training
     • Enrolled additional 30 exercise participants in database
     • Correctly identified all blind samples using the database
Week 2 - Stretch goals and collaboration
     • Demonstrated RapidHIT 200 could be used in a mobile
       environment
     • Demonstrated ability to do additional sample types—contact
       lens, eye, ear, and nose swabs, blood, cigarette butts, hat, etc.
     • Trained others to train others
                            IntegenX was featured at the VIP day
 17 | Proprietary and IntegenX Confidential | 6/27/2012
Additional Product Lines

        Apollo 324™ Next Generation Sequencing
        Library Preparation System




19 | Proprietary and IntegenX Confidential | 6/27/2012
Apollo 324™: The Complete Solution

                                                         Apollo 324
Supports                                                  • Fully automated
 • Illumina                                               • 1¼ - 7 hours per run
 • Roche 454                                              • Up to 32 libraries
 • Life Tech PGM                                          • Platform agnostic
 • Life Tech                                              • Simple user interface
   SOLiD                                                  • Ready-to-Use™
                                                            Reagents
                                                          • $79,500 List price
                                                          • $55/sample for reagents

                                                         Simplest and most versatile library preparation solution

20 | Proprietary and IntegenX Confidential | 6/27/2012
Apollo 324™ Kits
 2011 Releases
         •      PrepX: 8 sample kit for Illumina DNA analysis
         •      PrepX 32: 32 sample kit for Illumina DNA analysis
         •      PrepX High: High cut for DNA samples such as ChIP-Seq
         •      PrepX SPIA RNA-Seq: NuGEN SPIA chemistry for RNA-Seq
 2012 Q1 Releases
         •      PrepX 32 Indexed: 32 sample indexed DNA
         •      PrepX PGM DNA Library: Ion Torrent DNA kit
         •      PrepX 454 DNA Library: FLX kit for Roche/454
 2012 Q2 Releases
         •      PrepX2: ~One hour 8 sample DNA Kit
         •      PrepX2 Exome DNA app note for DNA exome sequencing
 2012 Q3 Releases
         •      PrepX Total RNA: High performance lower cost RNA 8 sample kit
         •      PrepX Small RNA: 8 sample kit for small RNAs
 2012 Q4 Releases (anticipated)
         •      TissueX: Process raw tissue to DNA libraries
         •      PrepX2 48: 48 fast samples
21 | Proprietary and IntegenX Confidential | 6/27/2012
IntegenX Summary
IntegenX is a leader in sample preparation and sample-to-
answer solutions
IntegenX’s NGS platform is the simplest and most versatile
library preparation solution
Huge market opportunity in human identification
        • Sample-to-answer rapid human ID is now a reality
        • Rapid human identification will be a “killer app” that transcends life
          sciences
This market crosses multiple disparate segments
        • Law enforcement, defense, immigration
        • Life science tools, molecular diagnostics, applied markets, and
          consumer markets
             IntegenX leads the Rapid Human Identification market
22 | Proprietary and IntegenX Confidential | 6/27/2012
www.integenx.com
Proprietary and IntegenX Confidential | 6/27/2012

More Related Content

Similar to Integen X Corporate Introduction 6 15 2012

SILS 2015 - Innovation at GE Healthcare
SILS 2015 - Innovation at GE HealthcareSILS 2015 - Innovation at GE Healthcare
SILS 2015 - Innovation at GE HealthcareSherbrooke Innopole
 
Medical Imaging Seminar Company Presentations
Medical Imaging Seminar Company PresentationsMedical Imaging Seminar Company Presentations
Medical Imaging Seminar Company PresentationsSpace IDEAS Hub
 
Smart automation presentation 2011
Smart automation presentation 2011Smart automation presentation 2011
Smart automation presentation 2011SakuraEU
 
PreScouter + GE Healthcare: How will the Internet of Things Impact your Indus...
PreScouter + GE Healthcare: How will the Internet of Things Impact your Indus...PreScouter + GE Healthcare: How will the Internet of Things Impact your Indus...
PreScouter + GE Healthcare: How will the Internet of Things Impact your Indus...PreScouter
 
eSource, EMEA London, June 2006
eSource, EMEA London, June 2006eSource, EMEA London, June 2006
eSource, EMEA London, June 2006AsseroLtd
 
Lean six sigma_webinar_presentation_slides
Lean six sigma_webinar_presentation_slidesLean six sigma_webinar_presentation_slides
Lean six sigma_webinar_presentation_slidessondhiya
 
Lean in health care – crossing the hurdles final part 2
Lean in health care – crossing the hurdles final part 2Lean in health care – crossing the hurdles final part 2
Lean in health care – crossing the hurdles final part 2Satishkumar Durairajan
 
Cdsm 2011 bro (final)
Cdsm 2011 bro (final)Cdsm 2011 bro (final)
Cdsm 2011 bro (final)JBScott44
 
Spain Startup Pitches 6
Spain Startup Pitches 6Spain Startup Pitches 6
Spain Startup Pitches 6SpainStartUp
 
Echometrix Pitch Deck-Jan 2015
Echometrix Pitch Deck-Jan 2015Echometrix Pitch Deck-Jan 2015
Echometrix Pitch Deck-Jan 2015Jeff Dalsin
 
Geber Consulting - Big Data in Healthcare
Geber Consulting - Big Data in Healthcare Geber Consulting - Big Data in Healthcare
Geber Consulting - Big Data in Healthcare Martin Hiesboeck
 
Geber Consulting - Big Data in Healthcare
Geber Consulting - Big Data in Healthcare Geber Consulting - Big Data in Healthcare
Geber Consulting - Big Data in Healthcare Martin Hiesboeck
 
Bilcare corporate presentation
Bilcare corporate presentationBilcare corporate presentation
Bilcare corporate presentationBilcareltd
 
Open2012 sharing-best-practices-hopkins
Open2012 sharing-best-practices-hopkinsOpen2012 sharing-best-practices-hopkins
Open2012 sharing-best-practices-hopkinsthe nciia
 
C3N Project Webinar w. Ginger.io - Aug 21 2012
C3N Project Webinar w. Ginger.io - Aug 21 2012C3N Project Webinar w. Ginger.io - Aug 21 2012
C3N Project Webinar w. Ginger.io - Aug 21 2012C3NProject
 
C3N Project Webcast with Ginger.io - August 21, 2012
C3N Project Webcast with Ginger.io - August 21, 2012C3N Project Webcast with Ginger.io - August 21, 2012
C3N Project Webcast with Ginger.io - August 21, 2012Amy Martin
 

Similar to Integen X Corporate Introduction 6 15 2012 (20)

SILS 2015 - Innovation at GE Healthcare
SILS 2015 - Innovation at GE HealthcareSILS 2015 - Innovation at GE Healthcare
SILS 2015 - Innovation at GE Healthcare
 
Medical Imaging Seminar Company Presentations
Medical Imaging Seminar Company PresentationsMedical Imaging Seminar Company Presentations
Medical Imaging Seminar Company Presentations
 
Introducing Axiom One
Introducing Axiom OneIntroducing Axiom One
Introducing Axiom One
 
Smart automation presentation 2011
Smart automation presentation 2011Smart automation presentation 2011
Smart automation presentation 2011
 
PreScouter + GE Healthcare: How will the Internet of Things Impact your Indus...
PreScouter + GE Healthcare: How will the Internet of Things Impact your Indus...PreScouter + GE Healthcare: How will the Internet of Things Impact your Indus...
PreScouter + GE Healthcare: How will the Internet of Things Impact your Indus...
 
Dr. Ying Xiao: Radiation Therapy Oncology Group Bioinformatics
Dr. Ying Xiao: Radiation Therapy Oncology Group BioinformaticsDr. Ying Xiao: Radiation Therapy Oncology Group Bioinformatics
Dr. Ying Xiao: Radiation Therapy Oncology Group Bioinformatics
 
Zepto
ZeptoZepto
Zepto
 
eSource, EMEA London, June 2006
eSource, EMEA London, June 2006eSource, EMEA London, June 2006
eSource, EMEA London, June 2006
 
Lean six sigma_webinar_presentation_slides
Lean six sigma_webinar_presentation_slidesLean six sigma_webinar_presentation_slides
Lean six sigma_webinar_presentation_slides
 
Lean in health care – crossing the hurdles final part 2
Lean in health care – crossing the hurdles final part 2Lean in health care – crossing the hurdles final part 2
Lean in health care – crossing the hurdles final part 2
 
Cdsm 2011 bro (final)
Cdsm 2011 bro (final)Cdsm 2011 bro (final)
Cdsm 2011 bro (final)
 
Spain Startup Pitches 6
Spain Startup Pitches 6Spain Startup Pitches 6
Spain Startup Pitches 6
 
Echometrix Pitch Deck-Jan 2015
Echometrix Pitch Deck-Jan 2015Echometrix Pitch Deck-Jan 2015
Echometrix Pitch Deck-Jan 2015
 
Geber Consulting - Big Data in Healthcare
Geber Consulting - Big Data in Healthcare Geber Consulting - Big Data in Healthcare
Geber Consulting - Big Data in Healthcare
 
Geber Consulting - Big Data in Healthcare
Geber Consulting - Big Data in Healthcare Geber Consulting - Big Data in Healthcare
Geber Consulting - Big Data in Healthcare
 
Bilcare corporate presentation
Bilcare corporate presentationBilcare corporate presentation
Bilcare corporate presentation
 
Open2012 sharing-best-practices-hopkins
Open2012 sharing-best-practices-hopkinsOpen2012 sharing-best-practices-hopkins
Open2012 sharing-best-practices-hopkins
 
Proximo Analytics Presentation April 2011
Proximo Analytics Presentation April 2011Proximo Analytics Presentation April 2011
Proximo Analytics Presentation April 2011
 
C3N Project Webinar w. Ginger.io - Aug 21 2012
C3N Project Webinar w. Ginger.io - Aug 21 2012C3N Project Webinar w. Ginger.io - Aug 21 2012
C3N Project Webinar w. Ginger.io - Aug 21 2012
 
C3N Project Webcast with Ginger.io - August 21, 2012
C3N Project Webcast with Ginger.io - August 21, 2012C3N Project Webcast with Ginger.io - August 21, 2012
C3N Project Webcast with Ginger.io - August 21, 2012
 

Integen X Corporate Introduction 6 15 2012

  • 1. Advanced Systems for Rapid Human Identification and Next Generation Sequencing Stevan Jovanovich, Ph.D. Proprietary and IntegenX Confidential | 6/27/2012
  • 2. Overview Who We Are • Growth-stage life science company, with commercial operations • Next Generation Sequencing products on the market • RapidHIT™ 200 Rapid Human ID System launching in Q3 • 2011 revenues of $4.5M: expected to more than triple in 2012 • All products covered by proprietary and/or >500 licensed patents • $75M in private equity; $24M in grants and contracts: DARPA, DTRA, DHS, NIH 2 | Proprietary and IntegenX Confidential | 6/27/2012
  • 3. Experienced Executive Management Team Stevan Jovanovich, Ph.D. – Co-Founder & CEO • VP of Global Research at Amersham Biosciences • ~$100 M funding at IntegenX with over 40 patents and publications Dennis Harris, Ph.D. – Co-Founder & CSO • CSO at Millipore and Serologicals Corporation • VP R&D North America Amersham Pharmacia Biotech David Smith – COO • CFO at Thoratec, Chiron, and Anergen • Leadership positions at Genentech, IBM and Syntex in North America, Asia and Europe Howard Goldstein – EVP, Commercial Affairs • 30+ years sales and marketing leadership building companies • VP Molecular Devices, Amnis, Incyte, MDCC; CEO at Entigen and Arcxis Ezra van Gelder – EVP, Research & Development • 20+ years engineering management • VP Development GE Healthcare, KLA Tencor Debara Frost – VP, Operations • VP Operations at Applied Biosystems • VP Customer Services and Distribution at Applied Biosystems 3 | Proprietary and IntegenX Confidential | 6/27/2012
  • 4. Product Solutions Rapid Human Identification – RapidHIT™ 200 Need Rapid answers for DNA human identification for defense, law enforcement, IQ, and DHS agencies Solution Sample-to-answer in less than 90 min Market DNA-based rapid identification $5B market in 2015 Next-Gen Sequencing Library Preparation – Apollo™ 324 Need Human error and lack of platform flexibility in DNA and RNA sequencing prep Solution Walk-away automation that serves multiple sequencing platforms Market $2B total sequencing market Room Temperature Stabilization and Storage – GenPlate™ and GenTegra™ Need Eliminate -80°C and cold chain Solution Inorganic stabilization and protection Market DNA-RNA based sample storage U.S. market $1B in 2015 4 | Proprietary and IntegenX Confidential | 6/27/2012
  • 5. DNA Forensics and Rapid Human Identification DNA is the ultimate biometric • Personal, but shows identity and kinship • Almost impossible to disguise or change • DNA evidence is standard in many parts of the world • CSI effect Short Tandem Repeats (STR) of DNA are used to identify people In the US, 13 STRs are used in the Combined DNA Index System (CODIS) Rapid DNA identification opens up new horizons • Screening of arrestees, detainees, immigrants, and evidence • Actionable intelligence 5 | Proprietary and IntegenX Confidential | 6/27/2012
  • 6. Rapid Human Identification: RapidHIT™ 200 The traditional HID process can take days to months: In Out Swabs DNA Blood Identity Semen Etc. Sample in, profile out Results in <90 minutes Minimal training required Point-of-action solution Produces CODIS data and can query databases to give answers 6 | Proprietary and IntegenX Confidential | 6/27/2012
  • 7. RapidHIT™ 200: The Complete Human ID Solution Sample 3 Control 4 Swabs 1 Anode 2 Buffer 7 | Proprietary and IntegenX Confidential | 6/27/2012
  • 8. RapidHIT™ 200 results data 02-29-2012 Sample 60M Buccal Swab Capillaries 2 and 6 8 | Proprietary and IntegenX Confidential | 6/27/2012
  • 9. RapidHIT ™ 200 Heterozygous peak balance is excellent Sample Sample Cap2: 60M Buccal Cap6: 60M Buccal Alleles Pk Ht (rfu) Pk Ht (rfu) PHR(%) Alleles Pk Ht (rfu) Pk Ht (rfu) PHR(%) D3S1358 17,17 100882 n/a n/a D3S1358 17,17 110501 n/a n/a THO1 6,7 13284 15819 84.0% THO1 6,7 16201 21311 76.0% D21S11 28,30 42017 37641 89.6% D21S11 28,30 44578 48880 91.2% D18S51 13,14 59075 54996 93.1% D18S51 13,14 61880 61370 99.2% PentaE 7,10 32751 32799 99.9% PentaE 7,10 34899 30145 86.4% D5S818 12,12 137731 n/a n/a D5S818 12,12 144917 n/a n/a 87% 83% D13S17 9,13 45463 40397 88.9% D13S17 9,13 53851 36820 68.4% D7S820 10,11 56523 44707 79.1% D7S820 10,11 48710 46579 95.6% D16S539 8,12 29209 23011 78.8% D16S539 8,12 18606 27570 67.5% CSF1PO 10,12 30609 38897 78.7% CSF1PO 10,12 29716 29261 98.5% PentaD 11,13 35174 30636 87.1% PentaD 11,13 46835 28881 61.7% Amel X,Y 37292 33314 89.3% Amel X,Y 36597 40877 89.5% vWA 15,18 19084 21006 90.9% vWA 15,18 27689 20669 74.6% D8S1179 13,13 49611 n/a n/a D8S1179 13,13 54902 n/a n/a TPOX 9,10 6724 5765 85.7% TPOX 9,10 6230 6932 89.9% FGA 19,19 19350 n/a n/a FGA 19,19 15718 n/a n/a 9 | Proprietary and IntegenX Confidential | 6/27/2012
  • 10. Rapid DNA-based Human Identification Markets Law Enforcement • Real-time screening of arrestees • Property crimes and non-evidentiary samples • Forensic identification and casework samples • Terrorists and organized crime 12 | Proprietary and IntegenX Confidential | 6/27/2012
  • 11. RapidHIT 200 Will Help Solve Property Crime DNA is highly effective for property crime investigation Backlogs in crime labs typically prevent use of DNA for property crimes Deployment of RapidHIT 200 will allow police to quickly focus investigations and clear cases Start of DNA use for high volume crimes Effectiveness and Cost Efficiency of DNA Evidence in Volume Crime - Denver Colorado Site Summary Simon Ashikhmin et al 15 | Proprietary and IntegenX Confidential | 6/27/2012
  • 12. Rapid DNA-based Human Identification Markets Defense • Identifying the opposition in asymmetric warfare • Field-based antiterrorism • Identifying suspects in raids • Using DNA to unravel the network • Linking IEDs to bomb makers • Finding captured soldiers IntegenX is funded to develop and deliver systems to DoD 16 | Proprietary and IntegenX Confidential | 6/27/2012
  • 13. DoD Field Demonstration, May 2012 DoD Joint Forces Invite-Only Capabilities Demonstration • Goal = Field forward capabilities for the war-fighter (Actionable Intelligence) • Format = Hands-on, tactical scenarios Week 1 - Prove your technology • Operational by non-expert personnel - 9 min training • Enrolled additional 30 exercise participants in database • Correctly identified all blind samples using the database Week 2 - Stretch goals and collaboration • Demonstrated RapidHIT 200 could be used in a mobile environment • Demonstrated ability to do additional sample types—contact lens, eye, ear, and nose swabs, blood, cigarette butts, hat, etc. • Trained others to train others IntegenX was featured at the VIP day 17 | Proprietary and IntegenX Confidential | 6/27/2012
  • 14. Additional Product Lines Apollo 324™ Next Generation Sequencing Library Preparation System 19 | Proprietary and IntegenX Confidential | 6/27/2012
  • 15. Apollo 324™: The Complete Solution Apollo 324 Supports • Fully automated • Illumina • 1¼ - 7 hours per run • Roche 454 • Up to 32 libraries • Life Tech PGM • Platform agnostic • Life Tech • Simple user interface SOLiD • Ready-to-Use™ Reagents • $79,500 List price • $55/sample for reagents Simplest and most versatile library preparation solution 20 | Proprietary and IntegenX Confidential | 6/27/2012
  • 16. Apollo 324™ Kits 2011 Releases • PrepX: 8 sample kit for Illumina DNA analysis • PrepX 32: 32 sample kit for Illumina DNA analysis • PrepX High: High cut for DNA samples such as ChIP-Seq • PrepX SPIA RNA-Seq: NuGEN SPIA chemistry for RNA-Seq 2012 Q1 Releases • PrepX 32 Indexed: 32 sample indexed DNA • PrepX PGM DNA Library: Ion Torrent DNA kit • PrepX 454 DNA Library: FLX kit for Roche/454 2012 Q2 Releases • PrepX2: ~One hour 8 sample DNA Kit • PrepX2 Exome DNA app note for DNA exome sequencing 2012 Q3 Releases • PrepX Total RNA: High performance lower cost RNA 8 sample kit • PrepX Small RNA: 8 sample kit for small RNAs 2012 Q4 Releases (anticipated) • TissueX: Process raw tissue to DNA libraries • PrepX2 48: 48 fast samples 21 | Proprietary and IntegenX Confidential | 6/27/2012
  • 17. IntegenX Summary IntegenX is a leader in sample preparation and sample-to- answer solutions IntegenX’s NGS platform is the simplest and most versatile library preparation solution Huge market opportunity in human identification • Sample-to-answer rapid human ID is now a reality • Rapid human identification will be a “killer app” that transcends life sciences This market crosses multiple disparate segments • Law enforcement, defense, immigration • Life science tools, molecular diagnostics, applied markets, and consumer markets IntegenX leads the Rapid Human Identification market 22 | Proprietary and IntegenX Confidential | 6/27/2012
  • 18. www.integenx.com Proprietary and IntegenX Confidential | 6/27/2012